Efficacy of somatostatin analogue (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs)

#3335

Introduction: Currently, there is minimal published data on the efficacy of SSAs for well-differentiated G3 NETs. Randomized trials have demonstrated a progression-free survival (PFS) benefit and limited response for lower grade 1-2 NETs, but the optimal therapy for metastatic G3 NETs is unknown.

Aim(s): We sought to evaluate the efficacy of SSAs in G3 NETs.

Materials and methods: We performed a retrospective analysis of patients treated with SSAs for metastatic G3 NETs. Inclusion criteria were: Centrally reviewed pathology confirming well-differentiated morphology, G3 based on WHO classification, SSA monotherapy, and radiological data available to assess response. Patients who had prior lines of treatment were included as long they subsequently were treated with single-agent SSA. Poorly differentiated tumors were excluded. The primary endpoint was PFS. Best overall response was determined by RECIST 1.1.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: McGarrah P

Authors: McGarrah P, Liu A, Hobday T, Starr J, Kendi A,

Keywords: somatostatin analogues, lanreotide, octreotide, well-differentiated grade 3 neuroendocrine tumor, G3net, G3nen,